<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05073094</url>
  </required_header>
  <id_info>
    <org_study_id>BETABLOCK-21</org_study_id>
    <nct_id>NCT05073094</nct_id>
  </id_info>
  <brief_title>Esmolol for Myocardial Protection in Hypertrophic Obstructive Cardiomyopathy</brief_title>
  <official_title>Myocardial Protection With Esmolol in Patients With Hypertrophic Obstructive Cardiomyopathy Undergoing Surgery Under Cardiopulmonary Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meshalkin Research Institute of Pathology of Circulation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meshalkin Research Institute of Pathology of Circulation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Perioperative blockage of beta-adrenoreceptors is widely used in cardiac and non-cardiac&#xD;
      surgery to reduce the rate of cardiovascular complications. Several randomized-controlled&#xD;
      studies and meta-analysis showed that esmolol reduces the incidence of myocardial ischemia&#xD;
      and arrhythmias in cardiac surgery as well as enhances postoperative cardiac performance. No&#xD;
      studies assessed the influence of esmolol in patients with hypertrophic obstructive&#xD;
      cardiomyopathy undergoing cardiac surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 6, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak concentration of Troponin I</measure>
    <time_frame>From the randomization to the postoperative day 3 (POD 3)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The need for (yes/no) inotropic agents</measure>
    <time_frame>through study completion, an average of 4 weeks</time_frame>
    <description>Number of patients requiring inotropic support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The need for (yes/no) defibrillation</measure>
    <time_frame>through study completion, an average of 4 weeks</time_frame>
    <description>Number of patients requiring defibrlillation after removal of aortic cross clamp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of new-onset moderate and severe arrhythmias of cardiac arrest</measure>
    <time_frame>through study completion, an average of 4 weeks</time_frame>
    <description>Number of patients with arrhythmias</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction</measure>
    <time_frame>through study completion, an average of 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak serum creatinine concentration</measure>
    <time_frame>through study completion, an average of 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of acute kidney injury</measure>
    <time_frame>through study completion, an average of 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>through study completion, an average of 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU stay</measure>
    <time_frame>through study completion, an average of 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay</measure>
    <time_frame>through study completion, an average of 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day all-cause mortality</measure>
    <time_frame>through study completion, an average of 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of diastolic dysfunction</measure>
    <time_frame>through study completion, an average of 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The dosage of inotropic agents (inotropic score)</measure>
    <time_frame>through study completion, an average of 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hypertrophic Obstructive Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Esmolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg/kg (max. 100 mg) as a bolus before aortic cross-clamping and 2 mg/kg (max. 200 mg) in the cardioplegia solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Equivalent volume of saline as a bolus before aortic cross-clamping and in the cardioplegic solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esmolol</intervention_name>
    <description>Esmolol injected intravenously and added to cardioplegia solution</description>
    <arm_group_label>Esmolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Equivalent volume of placebo (saline) as a bolus before aortic cross-clamping and in the cardioplegic solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Patient with hypertrophic obstructive cardiomyopathy undergoing surgery under&#xD;
             cardiopulmonary bypass&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of adverse effects on esmolol&#xD;
&#xD;
          -  Urgent/emergent surgery&#xD;
&#xD;
          -  Administration of esmolol in 30 days before randomization&#xD;
&#xD;
          -  Participation in other randomized trial during same hospitalization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vladimir Lomivorotov</last_name>
    <phone>+79139164103</phone>
    <email>vvlom@mail.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexander Bogachev-Prokophiev</last_name>
    <email>bogachev.prokophiev@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>E. Meshalkin National Medical Research Center</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir Lomivorotov, MD</last_name>
      <email>vvlom@mail.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/33451954/</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/27932571/</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/29398384/</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>October 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esmolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

